Veracyte, Inc. Overview
Pro stress-test →Veracyte is a global diagnostics company that empowers clinicians with high-value insights to guide and assure patients at pivotal moments in the race to diagnose and treat cancer, with tests that help patients avoid unnecessary procedures and speed time to diagnosis and appropriate treatments. Tests include thyroid, prostate, breast, bladder and lung cancers, as well as interstitial lung diseases.
Strategic Profile
Pro stress-test →The company raised its full-year 2025 revenue guidance to a range of $506 million to $510 million, driven by its core tests like Decipher and Afirma, all while maintaining a strong gross margin of 68.5%. Recent inclusion of their Decipher prostate test in NCCN guidelines and the strategic push into minimal residual disease (MRD) testing demonstrates their business model evolution.
Competitive Landscape
Pro stress-test →Veracyte has established a strong portfolio of tests for various cancers, including prostate, thyroid, breast, and bladder with a focus on providing clinicians with critical insights for cancer diagnosis and treatment. The company operates in the competitive genomic diagnostics space alongside players like Myriad Genetics, Castle Biosciences, and Guardant Health, competing primarily on test accuracy, clinical validation, and reimbursement coverage.
Industry Context
Veracyte, Inc. operates in Molecular Diagnostics / Genomic Cancer Testing.
Key facts
Founded: 2006 · Headquarters: South San Francisco, California · Employees: 824 · Revenue: $517.1M (2025) · Market cap: $2.9B